Evidence map›Paper›PMID 28372978›Full record

ArticleContraception2017

Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.

Richard E Haaland, Angela Holder, Tammy Evans-Strickfaden, Beatrice Nyagol, Mumbi Makanga, Boaz Oyaro, Felix Humwa, Tiffany Williams, Eleanor McLellan-Lemal, Mitesh Desai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contraception, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 5 countries.

Richard E HaalandDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: hyw9@cdc.gov.
Angela HolderDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: fka5@cdc.gov.
Tammy Evans-StrickfadenDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: tae0@cdc.gov.
Beatrice NyagolKEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: Bnyagol@kemricdc.org.
Mumbi MakangaKEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: mmakanga@kemricdc.org.
Boaz OyaroKEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: Boyaro@kemricdc.org.
Felix HumwaKEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: FHumwa@kemricdc.org.
Tiffany WilliamsICF International, Assigned to Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA 30329. Electronic address: wuq0@cdc.gov.
Eleanor McLellan-LemalDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: egm4@cdc.gov.
Mitesh DesaiDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: gdo5@cdc.gov.
Michael J HueyEmory University Student Health Services, Emory University School of Medicine, 1525 Clifton Road, Atlanta, GA, USA 30322. Electronic address: mhuey@emory.edu.
Centers for Disease Control and Prevention · USKenya Medical Research Institute · KEEmory University · USKema International (Netherlands) · NL

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectiveThis study sought to measure residual contraceptive hormone levels in vaginal rings as an adherence marker for monitoring product use in clinical trials. STUDY

designResidual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were compared to those from 16 women who used NuvaRing® as their contraceptive choice.

resultsTwenty-one (81%) clinical trial rings had contraceptive hormone levels within the range of those used as a contraceptive choice. Five returned rings had unused or discordant levels of residual contraceptive hormones.

conclusionResidual vaginal ring drug levels could help assess adherence in clinical trials.

Indexed as

Contraceptive Devices, FemalePatient ComplianceAdministration, IntravaginalClinical Trials as TopicContraceptive Agents, FemaleDesogestrelDrug CombinationsEthinyl EstradiolFemaleHumansKenyaUnited StatesContraceptive Agents, FemaleDesogestrelDrug CombinationsEthinyl EstradioletonogestrelNuvaRingAdherenceContraceptionHIVMultipurpose technologyVaginal ring

Identifiers

PMID28372978
PMCPMC5551387
OpenAlexW2598545196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.